biostudies-literatureUnknown3(4)Zheng YDiffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.Blood science (Baltimore, Md.)136-148https://www.ebi.ac.uk/biostudies/studies/S-EPMC8975004biostudies-literatureImmune targeted therapy for diffuse large B cell lymphoma.PMC8975004Yuan TZheng YDing SSi JTian CfalseImmune targeted therapy for diffuse large B cell lymphoma.Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.2021-01-01T00:00:00Z2021 Oct2025-04-05T00:40:01.338Z2025-04-05T00:40:01.338ZS-EPMC89750043540284610.1097/BS9.0000000000000095